ArticlePharmacological reports : PR2024
Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus.
Daniel Oliveira Silva Martins et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it